CAMBRIDGE, England, February 19, 2026--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
Synthego, a provider of genome editing solutions, and bit.bio, a synthetic biology firm, said that they are expanding their strategic partnership to work on a platform for implementing synthetic ...
CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...
The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...
Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...
Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results